Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Enzolytics Inc ENZC

Healthcare Biotechnology
Enzolytics, Inc. is a drug development company. The Company is engaged in the commercialization of its proteins and monoclonal antibodies for the treatment of debilitating infectious diseases. Its patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF) for the treatment of human immunodeficiency virus/ acquired immunodeficiency syndrome (HIV/AIDS). It has a technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases which is being employed to produce monoclonal antibody therapeutics for treating the Coronavirus (SARS-CoV-2), HIV-1 and the Feline Leukemia virus. The Company also plans to produce mAbs targeting many other viruses, including HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA).


OTCPK:ENZC - Post by User

Enzolytics Inc
<< Previous
 Bullboard Posts
User Avatar Image
(164)
•••
Post by whytestockson Jul 31, 2024 5:46pm
30 Views
Post# 36157126

Enzolytics, Inc. and the Bulgarian Academy of Sciences Initi

Enzolytics, Inc. and the Bulgarian Academy of Sciences Initi
News; $ENZC Enzolytics, Inc. and the Bulgarian Academy of Sciences Initiate a Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/AIDS ApplicationsAs well as Diabetes, Multiple Sclerosis and Other Diseases ALLEN, TX / ACCESSWIRE / July 31, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (" enzolytics.com" ) (the "Company") announced today that the Company and the Department of Immunology, Bulgarian Academy of Science The Stephan Angeloff...ENZC - Enzolytics, Inc. and the Bulgarian Academy of Sciences Initiate a Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/AIDS Applications

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities